Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

The numbers aren’t all bad in biotech. But you’d be forgiven if you thought they were. And you’d be in good company. Once again, Chris Dokomajilar at DealForma has been checking the data for us ...